SRT2104 inhibited activation of coagulation , as reflected by lower plasma levels of the prothrombin fragment F1 +2 ( mean peak levels 57.9 % [ p < 0.05 ] and 64.2 % [ p < 0.05 ] after single and repeated SRT2104 administration , respectively , relative to those measured after placebo treatment ) .